However, a multicentre clinical trial using the dimeric TNF-binding fusion protein etanercept as a treatment of patients with moderate to severe alcohol hepatitis failed because of serious adverse events such as increased infection rates and a significantly higher mortality rate after 6 months [52], clearly indicating that TNF blockade is not suitable for treatment of patients with ALD. Here, TNF is linked to infection.